复方芪麻胶囊对颈动脉粥样硬化斑块干预作用的机制

梁文坚; 王清海

doi:10.13422/j.cnki.syfjx.20181819

您当前的位置：

首页 >

文章列表页 >

复方芪麻胶囊对颈动脉粥样硬化斑块干预作用的机制

临床 | 更新时间：2024-01-04

- 复方芪麻胶囊对颈动脉粥样硬化斑块干预作用的机制
- Intervention Mechanism and Safety of Compound Qima Capsule on Carotid Atherosclerosis Plaques
- 中国实验方剂学杂志 2018年24卷第19期页码：189-194
- 作者机构：
- 作者简介：
- 基金信息：
  
  国家中医临床研究基地业务建设科研专项（JDZX2015145）;广东省中医药局建设中医药强省专项（粤中医办函[2015]102号）;广东省中医药局科研课题项目（20151010）
- DOI：10.13422/j.cnki.syfjx.20181819
  中图分类号： R259
- 纸质出版日期：2018
- 稿件说明：
移动端阅览
梁文坚, 王清海. 复方芪麻胶囊对颈动脉粥样硬化斑块干预作用的机制[J]. 中国实验方剂学杂志, 2018,24(19):189-194.

LIANG Wen-jian, WANG Qing-hai. Intervention Mechanism and Safety of Compound Qima Capsule on Carotid Atherosclerosis Plaques[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(19): 189-194.
梁文坚, 王清海. 复方芪麻胶囊对颈动脉粥样硬化斑块干预作用的机制[J]. 中国实验方剂学杂志, 2018,24(19):189-194. DOI： 10.13422/j.cnki.syfjx.20181819.

LIANG Wen-jian, WANG Qing-hai. Intervention Mechanism and Safety of Compound Qima Capsule on Carotid Atherosclerosis Plaques[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(19): 189-194. DOI： 10.13422/j.cnki.syfjx.20181819.

摘要

目的：通过观察复方芪麻胶囊治疗颈动脉粥样硬化斑块的临床效果，探求其干预作用机制及安全性。方法：将80例颈动脉粥样硬化患者随机分为对照组和观察组，各40例。两组均给予阿托伐他汀钙片口服，观察组加用复方芪麻胶囊口服，共治疗6个月。比较两组治疗前后各项指标的变化以评估疗效；检测治疗前后双侧颈动脉内膜-中层厚度（IMT）和颈动脉斑块面积；检测治疗前后甘油三酯（TG），总胆固醇（TC），高密度脂蛋白胆固醇（HDL-C）和低密度脂蛋白胆固醇（LDL-C）水平；检测治疗前后血清炎症因子白细胞介素-6（IL-6），肿瘤坏死因子-α（TNF-α），基质金属蛋白酶-9（MMP-9）水平；检测治疗前后血管内皮损伤指标一氧化氮（NO），内皮素-1（ET-1），6-酮前列腺素F1α（6-Reto-PGF1α）水平；以及不良反应情况。结果：治疗后，观察组的总有效率为95.00%，显著高于对照组的82.50%（P<0.05）。与对照组比较，观察组双侧颈动脉斑块面积和IMT明显降低，治疗后的血脂水平（TC，TG，LDL-C）明显降低（P<0.05）；血管内皮功能明显改善（P<0.05）；炎症因子明显降低（P<0.05）。两组患者治疗期间均无不良反应发生。结论：经过复方芪麻胶囊干预治疗颈动脉粥样硬化，颈动脉斑块面积显著缩小，IMT明显变薄，引起或加重颈动脉粥样硬化的各项实验室指标均明显改善；推测复方芪麻胶囊可能是通过降脂、抑制炎症反应、改善血管内皮功能等机制干预颈动脉粥样硬化斑块；其安全性良好。

Abstract

Objective: To explore the intervention mechanism and safety of compound Qima capsule in the treatment of carotid atherosclerosis plaques by observing its clinical efficacy. Method: Eighty patients with carotid atherosclerosis plaques were randomly divided into control group and treatment group (40 cases in each group). Patients in control group were treated with atorvastatin calcium tablets for 6 months. Patients in treatment group were additionally treated with compound Qima capsule for 6 months. The changes in the indicators were compared and the efficacy was assessed in both groups. Before and after treatment

thickness of carotid intima of the carotidartery (IMT) and atherosclerotic plaque area were detected by color Doppler ultrasound; levels of triglycerides (TG)

total cholesterol (TC)

high density lipoprotein-C (HDL-C) and low density lipoprotein-C (LDL-C) were detected; level of nitric oxide(NO)

endothelin-1(ET-1) and 6-ketone prostaglandin F1 α (6-Reto-PGF1α) were detected. Levels of interleukin-6 (IL-6)

tumor necrosis factor-α(TNF-α)

and matrix metalloproteinases-9 (MMP-9) were also detected.In addition

adverse drug reactions were compared between two groups. Result: After treatment

the total effective rate in treatment group was significantly higher than that in control group (P<0.05). By comparison with control group

the blood lipid levels and inflammatory factors in treatment group were significantly reduced (P<0.05)

vascular endothelial function was significantly improved (P<0.05)

bilateral carotid plaque area and carotid intima-media thickness were significantly reduced after treatment (P<0.05). There were no adverse drug reactions in both groups during the treatment. Conclusion: Compound Qima capsule can significantly decrease the bilateral carotid plaque area and carotid intima-media thickness

and improve the symptoms of carotid atherosclerosis with high safety for patients with carotid atherosclerosis plaques

and the mechanism may be related to regulating lipid metabolism

improving the endothelial function and anti-inflammatory response.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

茱萸丸治疗痰浊阻遏型高脂血症合并颈动脉粥样硬化的随机对照临床观察

口服中药治疗冠心病合并颈动脉粥样硬化疗效的贝叶斯网状Meta分析

化痰通络方对高血压颈动脉粥样硬化斑块易损性的影响

槲皮素抗脑缺血再灌注损伤作用机制研究进展

中药鼻用制剂的现代研究进展